NCT00675246

Brief Summary

This study aims to determine the effectiveness of antenatal corticosteroid therapy in late preterm babies. The investigators hypothesis is corticoid accelerates fetal lung maturation even after 34 weeks and reduces risk of respiratory distress syndrome and other neonatal morbidities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
320

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2008

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

May 7, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 9, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

June 9, 2010

Status Verified

June 1, 2010

Enrollment Period

2 years

First QC Date

May 7, 2008

Last Update Submit

June 8, 2010

Conditions

Keywords

corticoid therapyfetal lung maturationlate pretermrespiratory distress syndromeneonatal death

Outcome Measures

Primary Outcomes (1)

  • neonatal respiratory distress

    neonatal period (28 days of life)

Secondary Outcomes (4)

  • during of neonatal hospitalization

    neonatal period (28 days of life)

  • neonatal oxygen requirement

    neonatal period (28 days of life)

  • neonatal sepsis

    neonatal period (28 days of life)

  • neonatal death

    neonatal period (28 days of life)

Study Arms (1)

A

EXPERIMENTAL

Antenatal corticoid therapy

Drug: Betamethasone

Interventions

IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)

Also known as: CELESTONE SOLUSPAN (MANTECORP)
A

Eligibility Criteria

Age18 Years - 49 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Pregnancy between 34 and 36 weeks
  • Confirmed gestational age (LMP, USG)
  • Alive fetus
  • Imminent risk of preterm delivery

You may not qualify if:

  • Multiple pregnancy
  • Major fetal malformations
  • Comproved fetal lung maturity
  • Maternal or fetal indication for immediate interruption of pregnancy
  • Maternal hemorrhagic syndromes (placenta previa, abruptio placenta)
  • Chorioamnionitis
  • Chronic use of corticosteroids
  • Previous use of corticosteroids for fetal lung maturation in the current pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Materno Infantil Prof. Fernando Figueira

Recife, Pernambuco, 50070550, Brazil

Location

Related Publications (1)

  • Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011 Apr 12;342:d1696. doi: 10.1136/bmj.d1696.

MeSH Terms

Conditions

Hyaline Membrane DiseaseRespiratory Distress SyndromePerinatal Death

Interventions

Betamethasonebetamethasone acetate phosphate

Condition Hierarchy (Ancestors)

Respiratory Distress Syndrome, NewbornLung DiseasesRespiratory Tract DiseasesRespiration DisordersInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Melania Amorim, MD, PhD

    Instituto Materno Infantil Prof. Fernando Figueira

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 7, 2008

First Posted

May 9, 2008

Study Start

May 1, 2008

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

June 9, 2010

Record last verified: 2010-06

Locations